Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs, but that number falls ...

In Michigan, the state’s largest insurer has tightened restrictions around medications like Wegovy. Patients are panicking.

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Starting in the new year, the region’s largest health insurer will no longer cover popular diabetes drugs for the purposes of ...

What a year! What do you think was the most important news in the United States in 2024? This list probably doesn’t reflect that. Rather, it shows what you, the readers, were looking at on ...

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.

Semaglutide drugs, like Ozempic and Wegovy, have helped millions of Americans lose weight, reduce cravings and better manage ...

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...

Consumers who take copies of the popular weight loss and diabetes drug tirzepatide will likely need to find a new source for these medications early next year. On Thursday, the Food and Drug ...